Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.

@article{Dai2018ImpactO5,
  title={Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.},
  author={Charles Dai and Vishnu Prasad Kaushik Ganesan and Joseph R. N. Zabell and Yaw A. Nyame and Nima Almassi and Daniel J. Greene and Daniel R Hettel and Chad A. Reichard and Samuel C Haywood and Hans Chin Arora and Anna M Zampini and Alice Crane and Jianbo Li and Ahmed Elshafei and Cristina Magi-Galluzzi and Robert J. Stein and Khaled Fareed and Michael Chi Gong and J. Stephen Jones and Eric A Klein and Andrew J. Stephenson},
  journal={The Journal of urology},
  year={2018},
  volume={199 2},
  pages={445-452}
}
PURPOSE We determined the effect of 5α-reductase inhibitors on disease reclassification in men with prostate cancer optimally selected for active surveillance. MATERIALS AND METHODS In this retrospective review we identified 635 patients on active surveillance between 2002 and 2015. Patients with favorable cancer features on repeat biopsy, defined as absent Gleason upgrading, were included in the cohort. Patients were stratified by those who did or did not receive finasteride or dutasteride… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS